Aaron Royston serves as Executive at Akero Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Aaron Royston has executed 7 insider transactions totaling $19.0M, demonstrating a bullish approach to their equity position. Their most recent transaction on Oct 25, 2021 involved exercising options for 3,684,769 shares valued at $0.
Aaron Royston currently holds 3,684,769 shares of Akero Therapeutics, Inc. (AKRO), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Aaron Royston has been a net buyer of AKRO stock. They have purchased $19.0M and sold $0 worth of shares.
Aaron Royston's most recent insider trade was on Oct 25, 2021, when they sold 3,684,769 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $16.00 |
| Discretionary |
| Jun 29, 2021 | ELEV | $10.0M | Purchase | 625,000 | $16.00 | Discretionary |
| Jun 29, 2021 | ELEV | $0 | Conversion | 1,983,167 | $N/A | Discretionary |
| Jun 24, 2019 | AKRO | $0 | Conversion | 3,469,759 | $N/A | Discretionary |
| Jun 24, 2019 | AKRO | $4.0M | Purchase | 250,000 | $16.00 | Discretionary |
| Jun 24, 2019 | AKRO | $0 | Conversion | 235,099 | $N/A | Discretionary |